Major Policy Advances Supporting Pediatric Outpatient WGS
Today, 80% of people in the United States have access to whole-exome sequencing (WES), often as a second-line test, when traditional chromosomal microarray or other targeted tests have not led to a diagnosis for a patient. As payers review recent publications outlining the evidence of WGS superiority on the clinical and economic value, it becomes evident that the most efficient testing pathway to end – or better to prevent – a diagnostic odyssey for their beneficiaries is WGS access (first line in many policies). Towards this direction payers have started to offer beneficiaries access to first line WGS in patients with suspected complex genetic disease (e.g. neurodevelopmental delays) presented in the ambulatory setting, independent of age.
Outpatient coverage for WGS has greatly expanded in the last two years; approximately 80% of people in the United States will have access to WGS by June 2026. Multiple large private payers and 22 state Medicaid plans currently cover WGS. Additionally, several lab benefit managers, including eviCore, Carelon*, Avalon**, Concert and MCG cover WGS.
*Effective June 14, 2026
22 State Medicaid Plans Currently Cover Outpatient WGS
Approximately 44 Million Covered Lives for WGS under State Medicaid
*Data courtesy of GeneDx as of January 1, 2026. Contact the payer for specific coverage details. Coverage is at the health plan’s discretion, may be interpreted differently, and can change without notice.
Medicaid Coverage of Rapid Genome Sequencing in Acute Care Setting
*Data courtesy of Genomic Answers for Children’s Health Alliance as of January 1, 2026. Contact the payer for specific coverage details. Coverage is at the health plan’s discretion, may be interpreted differently, and can change without notice.
Inpatient (NICU) Coverage of rapid WGS
Coverage for rapid WGS in acute settings, such as the Neonatal Intensive Care Unit (NICU) and Pediatric ICU (PICU), is increasing as the clinical and economic value of the test build evidence across studies. Several children’s hospitals across the United States have participated in research studies to demonstrate how implementing rapid WGS in their NICU/PICUs improved outcomes including time to diagnosis, diagnostic yield, and subsequent changes to patient management.
Project Baby Bear in California found that WGS can reduce healthcare expenditures by avoiding unnecessary procedures/tests and reducing the infant’s the length of stay in the NICU. The study yielded an average of $13,526 savings per infant tested, creating an economic model where the savings support the cost of running WGS.
The Rady Children’s Institute for Genomic Medicine keeps an up-to-date list of all private payers and state Medicaid plans which cover rapid WGS.
California Blue Shield was the first major payer to issue a coverage policy for rapid, diagnostic WGS in NICU infants and trios in July 2019. Fast-forwarding to 2023, 50M covered lives (~1 in 5 total covered lives) can access WGS in acute settings (Medicaid: 30% vs. Commercial: 15%).
*as of June 2023. Data on file.
To discuss additional questions regarding payer coverage with a member of the Illumina Market Access team, please send an email to: medinfo@illumina.com
The information on this website is specific to U.S. payers only. All information is based on publicly available data and is subject to individual payer policies. Contact payers directly for accurate information.
